SCHEMBL30639747

SCHEMBL30639747

C[C@@H](Nc1ccc(-c2cncc(C(F)(F)F)c2)cn1)c1ccc(F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
GPR55 Q9Y2T6 19/20 1.00
PSEN1 P49768 1/20 0.51
PSEN2 P49810 1/20 0.51
APH1B Q8WW43 1/20 0.51
NCSTN Q92542 1/20 0.51
APH1A Q96BI3 1/20 0.51
PSENEN Q9NZ42 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26614500 1.00 GPR55 (1.00) GPR55PSEN1PSEN2APH1BNCSTN
SCHEMBL26614506 1.00 GPR55 (1.00) GPR55PSEN1PSEN2APH1BNCSTN
SCHEMBL26614606 0.84 GPR55 (1.00) GPR55PSEN1PSEN2APH1BNCSTN
SCHEMBL30639691 0.84 GPR55 (1.00) GPR55PSEN1PSEN2APH1BNCSTN
SCHEMBL26614515 0.84 GPR55 (1.00) GPR55PSEN1PSEN2APH1BNCSTN
SCHEMBL30639817 0.83 GPR55 (0.76) GPR55PSEN1PSEN2APH1BNCSTN
SCHEMBL26614713 0.83 GPR55 (0.76) GPR55PSEN1PSEN2APH1BNCSTN
SCHEMBL30639750 0.83 GPR55 (0.76) GPR55PSEN1PSEN2APH1BNCSTN
SCHEMBL26614508 0.83 GPR55 (0.76) GPR55PSEN1PSEN2APH1BNCSTN
SCHEMBL26614502 0.83 GPR55 (0.76) GPR55PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514788-A1 NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR Cerevance, Inc. (US) 2025-03-05 EP disclosed
WO-2023209368-A1 NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR Cerevance, Inc. (US) 2023-11-02 WO disclosed